Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN N versus NEO FRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN N versus NEO FRADIN.
CORDRAN N vs NEO-FRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
None Documented
None Documented
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic